Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

26.01.18	Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GlobeNewswire)
24.01.18	Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss (GlobeNewswire)
24.01.18	Novartis erzielt 2017 eine gute operative Performance sowie wegweisende Innovationen und ist gut gerüstet für die nächste Wachstumsphase (GlobeNewswire)
24.01.18	Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase (GlobeNewswire)
22.01.18	Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments (GlobeNewswire)
22.01.18	Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period (GlobeNewswire)
18.01.18	Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars (GlobeNewswire)
17.01.18	Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL (GlobeNewswire)
16.01.18	Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients (GlobeNewswire)
16.01.18	Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA (GlobeNewswire)
11.01.18	Novartis ernennt Elizabeth Barrett zur Chefin Onkologie (GlobeNewswire)
11.01.18	Novartis appoints Elizabeth Barrett as Oncology Head (GlobeNewswire)
09.01.18	Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** (GlobeNewswire)
04.01.18	Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) (GlobeNewswire)
03.01.18	Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer (GlobeNewswire)
22.12.17	Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label (GlobeNewswire)
22.12.17	Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma (GlobeNewswire)
15.12.17	Novartis gibt Rücktritt des Onkologie-Chefs bekannt (GlobeNewswire)
15.12.17	Novartis announces Oncology head to retire (GlobeNewswire)
11.12.17	Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study (GlobeNewswire)
10.12.17	Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer (GlobeNewswire)
08.12.17	Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine (GlobeNewswire)
07.12.17	Novartis tender offer for Advanced Accelerator Applications commences (GlobeNewswire)
06.12.17	Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to... (GlobeNewswire)
30.11.17	Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients (GlobeNewswire)
29.11.17	Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention (GlobeNewswire)
27.11.17	Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide® (GlobeNewswire)
20.11.17	Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children (GlobeNewswire)
15.11.17	Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania (GlobeNewswire)
14.11.17	Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy (GlobeNewswire)
14.11.17	New data reinforces clinical basis for switching to Sandoz biosimilar medicines (GlobeNewswire)
13.11.17	Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants (GlobeNewswire)
13.11.17	Novartis highlights its differentiated late stage pipeline at the R&D update and investor event (GlobeNewswire)
12.11.17	New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure (GlobeNewswire)
11.11.17	Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases (GlobeNewswire)
10.11.17	Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness (GlobeNewswire)
08.11.17	Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer (GlobeNewswire)
07.11.17	Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage (GlobeNewswire)
06.11.17	Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years (GlobeNewswire)
06.11.17	Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL (GlobeNewswire)
02.11.17	Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program (GlobeNewswire)
01.11.17	Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease (GlobeNewswire)
31.10.17	Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy (GlobeNewswire)
30.10.17	Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA (GlobeNewswire)
30.10.17	Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio (GlobeNewswire)
28.10.17	Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a (GlobeNewswire)
27.10.17	Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review (GlobeNewswire)
25.10.17	Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS (GlobeNewswire)
24.10.17	Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen (GlobeNewswire)
24.10.17	Novartis delivered growth on top and bottom line in all divisions in Q3 (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	73.50	1.66 %	K V
CieFinRichemont	128.90	0.98 %	K V
Part Grp Hldg	1’311.00	0.88 %	K V
Alcon	77.80	0.88 %	K V
ABB	51.66	0.78 %	K V
Swiss Life Hldg	688.80	-0.23 %	K V
Zurich Insur Gr	557.80	-0.53 %	K V
Kuehne+Nagel Int	212.10	-0.61 %	K V
Givaudan	3’862.00	-1.18 %	K V
Novartis	91.33	-1.82 %	K V

mehr

09:28		Freundlicher Handel in Frankfurt: TecDAX legt zum Start zu
09:28		STOXX-Handel: Euro STOXX 50 zum Start auf grünem Terrain
09:28		Mittwochshandel in Frankfurt: LUS-DAX beginnt Sitzung mit Gewinnen
09:28		SPI-Handel aktuell: SPI startet in der Verlustzone
09:28		Optimismus in Europa: STOXX 50 zum Start im Aufwind
09:28		LSE-Handel FTSE 100 startet im Minus